Clinical Training 1 (CT1) Day 4 Practice Exam

These questions are part of the practice quiz. Start practicing

• What is included in the 'subjective' part of the SOAP note?
• How should a clinician approach a patient who is non-compliant with treatment?
• What material aspects does the Synergy XD use to enhance usability?
• What was the percentage of TVF noted in the angiography group during the ULTIMATE trial?
• What is indicated by a proper documentation of a patient's medication history?
• What is the definition of axial strength in stents?
• Describe the 'Assessment' section of the SOAP note.
• Which feature of the Synergy XD stent aids in its trackability?
• What should be prioritized in a treatment plan?
• What insight did the AGENT IDE trial provide regarding AGENT DCB?
• What is the minimum size for MSA in the BSC's post stent workflow?
• What was the ST percentage recorded in the Senior trial?
• What is an adverse consequence associated with late stent thrombosis?
• What is a primary goal when conducting a patient assessment?
• What is a primary design consideration for drug-coated balloons (DCB)?
• In which section of the SOAP note would you document vital signs?
• Why is rapid absorption a critical design consideration for drug-coated balloons?
• What is the importance of vessel straightening in relation to MACE and in-stent restenosis (ISR)?
• Which factor can significantly hinder effective communication in clinical environments?
• How often should clinicians update their clinical skills?
• What are the key components of a neurological examination?
• What is the benefit of revising clinical skills regularly?
• What is the main purpose of informed consent?
• What is the recommended inflation time for a DCB?
• What major clinical benefit is associated with using a single stent versus overlapping stents?
• What is the difference between acute and chronic conditions?
• What best defines a propensity score?
• What is the significance of statistical power in clinical trials?
• What is a primary concern regarding non-compliance with DAPT?
• What is a recent exclusion criterion for the AGENT IDE trial?
• What was the DAPT length prescribed for high bleeding risk patients in the EVOLVE trial?
• Why is documentation important in clinical practice?
• What is the post dilatation limit for a 2.25 diameter in Synergy?
• Which of the following indicates a significant predictor of major adverse cardiovascular events (MACE)?
• What is a common barrier to effective communication in clinical settings?
• What was the maximum rated pressure for AGENT DCB with a size between 2-3 mm?
• What is the first class of recommendation among the three available?
• Which technique is commonly used for auscultation?
• Which of the following is one of the design factors that impact healing in stents?
• Which attribute ensures that a stent does not distort vessel architecture?
• Why is understanding common drug interactions crucial for healthcare providers?
• What design solution does AGENT provide for targeted transfer?
• Which of the following was NOT a key clinical characteristic of the DCB group in the AGENT IDE trial?
• Which of the following defines In-stent Restenosis (ISR)?
• Which of the following is true about extracellular matrix?
• What is meant by 'sustained retention' in the context of DCB design?
• Why is it crucial for clinicians to continuously update their knowledge and skills?
• What was the ST percentage for high bleeding risk patients in the EVOLVE trial?
• What is the purpose of a differential diagnosis?
• What is the longest Megatron stent diameter?
• Which treatment is typically not used for neointimal hyperplasia?
• What information does the 'Plan' section of the SOAP note typically include?
• Which factor does NOT contribute to a stent's deliverability?
• What is the nominal pressure for AGENT DCB?
• What is one of the factors to assess using HD-IVUS?
• What is an indication for using AGENT?
• Which treatment approach is effective for undersized or underexpanded stents?
• Which of the following is NOT a component of Target Vessel Failure (TVF)?
• What encompasses 'patient-centered care' in healthcare delivery?
• Which of the following describes the effect of a stent's profile in its design?
• What role does patient feedback play in clinical training?
• What does a P value of 0.05 indicate?
• What was the TLF rate for DCB in the AGENT IDE trial?
• What should a clinician do if a patient refuses treatment?
• On what type of balloon platform is the AGENT used?
• What is the length range for Synergy XD for a 2.5 mm size?
• How is neoatheroma or neoatherosclerosis characterized?
• What was the primary endpoint measured in the ULTIMATE trial?
• What is the common characteristic of neointimal tissue?
• Radial strength is mainly determined by which of the following factors?
• Where is the polymer applied on Synergy stents?
• How can a clinician effectively assess a patient's comprehension of medical instructions?
• What is the maximum percentage of plaque burden that is acceptable at the stent edge in BSC's post stent workflow?
• What is involved in the PREP step of the DCB procedure?
• How many patients were included in the final publishing of the AGENT IDE trial?
• What does an 'elevated white blood cell count' typically indicate?
• What does the abbreviation DAPT stand for?
• Which characteristic is important for the effectiveness of drug-coated balloons?
• How does a prospective study differ from a retrospective study?
• What are the diameters and proximal stent connectors for Synergy SV?
• Describe effective strategies for patient education.
• What is the range of DCB sizes available?
• What is the restenosis rate for drug-eluting stents (DES)?
• What is the first step in the DCB procedure process?
• Which method of guidance was compared in the ULTIMATE trial for DES implantation?
• What does it mean when a substance is described as proliferative?
• Which of the following best describes the term 'patient compliance'?
• What is restenosis primarily a response to?
• How does accurate medication reconciliation impact patient safety?
• What role does a cutting balloon play in treating vascular lesions?
• Why is it important to establish rapport with patients?
• What is the purpose of follow-up appointments in patient care?
• What does the term cytostatic mean?
• What was the DAPT recommendation for stable patients in the ASET trial?
• What is the AGENT design solution for sustained retention?
• What is the last step in the 5 steps of the DCB procedure?
• What is the definition of lipophilic?
• What does the acronym SOAP stand for in clinical documentation?
• What design solution is used by AGENT for rapid absorption?
• Which factor does NOT contribute to radial strength?
• What is cytotoxic defined as?
• What role does patient confidentiality play in clinical practice?
• Which treatment method is used for neoatherosclerosis?
• What is the TVF rate for IVUS-guided procedures 3 years post-ULTIMATE trial?
• How is radial strength defined in terms of stents?
• What class of recommendation does IVUS hold for complex PCI?
• How can clinicians enhance their communication skills?
• Why is it important to assess a patient's psychosocial history?
• In the context of clinical practice, what does it mean to be patient-centered?
• How long does the 2023 SCAI consensus recommend DAPT following a DCB procedure?
• What is the role of evidence-based practice in clinical training?
• What is relative risk reduction?
• What immediate action should be taken when a clinician observes a 'red flag' during an assessment?
• How long was the trial duration for patients in the Senior trial?
• In managing neoatherosclerosis, which device is complemented by an atherectomy?
• What is one of the main functions of a polymer in drug-eluting stents?
• What aspect is a key consideration from a patient's perspective regarding DAPT?
• Why is empathy considered a vital skill in clinical training?
• What is the main purpose of diagnostic tests in clinical practice?
• What does neointimal hyperplasia (NIH) result in?
• What is the length range available for DCBs?
• What do the design considerations for drug-coated balloons primarily focus on?
• What is a potential downside of having a permanent polymer on an implanted stent?
• What type of balloon is preferred for treating undersized or underexpanded stents?
• What is the size range for Synergy XD devices?
• What is the importance of conducting a medication history with a patient?
• For elderly patients in the Senior trial, what was the DAPT duration?
• What is one of the benefits of using single stents in clinical practice?
• Which stent design attribute is most important to physicians?
• What does IVL stand for in vascular treatment methods?
• What is essential for cell division in regard to extracellular matrix?
• Which of the following is NOT a cause of restenosis?
• What defines recoil in the context of stents?
• What is the significance of informed consent in clinical practice?
• In the context of atherosclerosis, what does neoatheroma primarily consist of?
• In a clinical trial, what is the purpose of having a control group?
• What is the goal of targeted transfer in drug delivery systems for vascular treatments?
• What is the primary role of strut thickness in stent design?
• What is the role of clinical guidelines in patient care?
• What size guide is compatible with all sizes of DCB?
• How can active listening benefit the clinician-patient relationship?
• This is a key method for managing pain effectively in patients.
• What was the 3-year target vessel failure (TVF) rate for the Angio group in the ULTIMATE trial?
• What is the main goal of health promotion in clinical practice?
• What is one of the key benefits of interdisciplinary collaboration in healthcare?
• What is the length range for Synergy XD for a 4.5 mm size?
• Which percentage of the DCB group had diabetes in the AGENT IDE trial?
• Why should clinicians regularly reflect on their practice?
• Why is it important to document the patient's medical history accurately?
• What is the primary characteristic of cobalt chromium used in Abbott stents?
• How can cultural sensitivity impact patient care?
• Why is accurate medication reconciliation essential in healthcare?
• What is one effective strategy for pain management in clinical practice?
• What is a characteristic of double-blind trials?
• How does Paclitaxel affect cell migration?
• What was a notable DAPT length for patients treated in the POEM trial?
• What is the function of extracellular matrix (ECM) in tissues?
• What is a core element of a successful treatment plan?
• What was the ST percentage in the AGENT IDE trial for POBA?
• What is one of the goals of HD-IVUS in evaluating stent failure?
• What factor most influences the timing of drug release in drug-eluting stents?
• What is the primary method of gathering objective data during a clinical exam?
• In the context of Synergy XD, what is the length range for a 2.25 mm device?
• Which endpoint showed a 51% risk reduction in the AGENT IDE trial?
• What does it mean to 'triage' a patient in clinical practice?
• When are both the drug and polymer from the Synchrony Bioabsorbable Polymer stent fully dissipated?
• What is the purpose of a physical examination?
• What aspect of DAPT directly affects patient quality of life?
• What characteristic defines microtubules?
• What is hyperplasia defined as?
• What are the diameters and proximal stent connectors for Synergy WH?
• What should be done after the SEE step in the DCB procedure?
• What endpoint should address the initial research objective of a clinical trial?
• What does the term 'red flag' signify in clinical assessments?
• Which of the following steps should a clinician take when conducting a physical examination?
• Which of the following is NOT a characteristic of Pivotal/IDE trial designs used for FDA approval?
• When should you repeat the PREP and SEE steps in the DCB procedure?
• Which design feature of the Synergy XD midshaft section increases flexibility?
• What is the primary focus of Clinical Training 1?
• How many connectors are located in the proximal region of the Megatron?
• What is the function of an excipient in pharmaceuticals?
• What should a clinician do if they encounter an ethical dilemma in practice?
• What does TLF stand for in the context of the AGENT IDE trial?
• What is an important aspect of effective patient communication?
• According to the ESC, what is the class recommendation for DCB in the treatment of ISR?
• Which of the following is essential for accurate clinical assessments?
• In trial development, what does the term "multi-center" imply?
• Which of the following is NOT a Synergy stent model?
• What is the name of the drug-coated balloon (DCB) coating?
• What role does patient education play in clinical practice?
• What types of cells primarily compose neointimal hyperplasia?
• What is the primary purpose of a thorough physical examination in clinical practice?
• What essential information is conveyed in a referral letter?
• What does neo-atherosclerosis refer to in the context of stent placement?
• What was the TLR rate for DCB in the AGENT IDE trial?
• What is a primary reason to perform a clinical trial?
• What percentage reduction in TVMI was observed in the AGENT IDE trial?
• What lengths are available for Megatron stents?
• Which of the following criteria must be met to treat an ISR lesion with a DCB?
• Which clinical skill involves taking a patient's medical history?
• For the treatment of NIH, which device is recommended?
• Which concern is NOT typically related to physician perspective on dual antiplatelet therapy (DAPT)?
• What alloy is used in BSC stents?
• Why is it important for clinicians to be aware of social determinants of health?
• What indicates that the lesion is optimized in the DCB procedure?
• How do clinical guidelines enhance patient care?
• What percentage of PCI procedures are associated with ISR?
• Why is regular training in clinical skills necessary for healthcare professionals?
• What aspect of care does 'patient-centered care' prioritize?
• What is the size range for Megatron stents?
• What are cranial nerves and why are they important in a neurological exam?
• What is one of the goals of using HD-IVUS in assessing stent failure?
• What does 'NIH' stand for in the context of vascular treatments?
• What was the Megatron stent designed and developed for?
• What does the term homogenous refer to?
• Which of the following is one of the five characteristics of the Gold Standard for trial development?
• Which characteristic is essential for a trial to be classified as randomized?